To help with the widespread efforts around anti-SARS drug discovery, Nanosyn has just developed a robust SARS-CoV2 S1-ACE2 interaction assay.
The SARS-CoV-2 virus uses surface Spike protein S1 to attack and anchor to a human cell. The Angiotensin Converting Enzyme 2 (ACE2) has been shown to serve as a receptor for the Spike protein S1. The interaction between S1 and ACE2 is the essential step during a viral infection, which mediates the virus fusion with a cellular membrane and consecutive entry of the virus into a human cell.
Therefore, disruption of the S1-ACE2 interaction by either a small molecule compound or specific antibody could provide an opportunity for anti-viral intervention. To help support this potential avenue of the anti-COVID-19 drug discovery, Nanosyn has developed a robust SARS-CoV2 S1-ACE2 interaction assay. The assay utilizes recombinant S1 and ACE2 proteins and a time- resolved FRET detection platform suitable for the evaluation of a high-volume of test compounds in high throughput format.
The assay utilizes recombinant S1 and ACE2 proteins and time-resolved FRET detection platform suitable for evaluation of high volumes of test compounds in high throughput format.